Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05959590 · ClinicalTrials.gov registry record · Phase 1
Ferumoxytol-enhanced Imaging of Osteomyelitis
A Phase 1 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05959590: Completed Phase 1 study, sponsored by University of New Mexico.
NCT05959590 is a Phase 1 study that has completed, run by University of New Mexico. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05959590, a Phase 1 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Diabetic foot infections contribute to 75,000 hospitalizations in the US each year. There is a lifetime incidence of 15-25% of foot infections in diabetics. The investigators hypothesize that ferumoxytol (FDA approved for use in CKD patients, unlike gadolinium) will improve the accuracy of MR imaging in the diagnosis of osteomyelitis by allowing for the specific imaging of macrophages that have taken up the iron-based compound. In this study the investigators will image 12 patients with suspected diabetic osteomyelitis using ferumoxytol-contrasted MRI, and evaluate the feasibility of this approach.
Primary Outcome
To measure the contrast changes of osteomyelitis on ferumoxytol-contrasted MRI.
Interventions
- DRUG Ferumoxides 11.2Mg Solution for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-02-12 |
| Est. Completion | 2019-08-12 |
| Phase | Phase 1 |
What the finished NCT05959590 record still lists
NCT05959590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Ferumoxides 11.2Mg Solution for Injection is the first listed.
NCT05959590 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05959590 about?
NCT05959590 is a clinical study titled "Ferumoxytol-enhanced Imaging of Osteomyelitis". Diabetic foot infections contribute to 75,000 hospitalizations in the US each year. There is a lifetime incidence of 15-25% of foot infections in diabetics. The investigators hypothesize that ferumoxytol (FDA approved for use in CKD patients, unlike gadolinium) will improve the accuracy of MR imagin...
What is the current status of trial NCT05959590?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-02-12. Estimated completion is 2019-08-12.
What interventions are being tested in trial NCT05959590?
The interventions under investigation include: Ferumoxides 11.2Mg Solution for Injection (DRUG).
Who is sponsoring clinical trial NCT05959590?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05959590's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI